Israeli cancer drug developer Biosight lists on NASDAQ
Categories: Capital Markets, Corporate and M&A
Biosight has merged with US immunotherapy company Advaxis at a company valuation of USD 280 million and will trade under the BSTX ticker.
Israeli cancer therapeutics developer Biosight has agreed to merge with US immunotherapy company Advaxis, which is traded on Wall Street with a market cap of USD 68 million. The move is an alternative for BioSight’s IPO or SPAC merger.
The merged company will be renamed Biosight Therapeutics and trade on Nasdaq under the BSTX ticker.
Morgan, Lewis & Bockius LLP and Herzog Fox & Neeman are serving as legal counsel to Advaxis. White & Case and Horn & Co. are serving as legal counsel to Biosight.
